<DOC>
	<DOCNO>NCT00539669</DOCNO>
	<brief_summary>Evaluate response rate Docetaxel combination Carboplatin Cisplatin first line chemotherapy epithelial ovarian cancer . Assess progression free survival , tolerance , duration response survival patient population .</brief_summary>
	<brief_title>TAX + Carboplatin Cisplatin 1st Line Post-Surgery Ovarian</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<criteria>Histologically confirm epithelial ovarian carcinoma . Patients peritoneal carcinomatosis also eligible , without necessarily histological proof primary source ovary , provide tumour mucinsecreting , evidence primary fallopian tube cancer ( see exclusion criterion ) . Female , age 18 FIGO stage IcIV without successful cytoreductive surgery stag laparotomy . Stage Ic patient limit malignant cell ascitic fluid , peritoneal washing tumour surface ovary Patients rupture capsule evidence stage Ic eligible entry study . ECOG performance status &gt; 2 Prior treatment chemotherapy radiotherapy . Patients , preexist fluid retention pleural effusion , pericardial effusion ascites exclude study , monitor closely deterioration . Efforts make determine cytological analysis whether significant preexist fluid collection due ovarian cancer , subsequent drainage recommend initiating chemotherapy . Inadequate bone marrow function define neutrophil &lt; 1.5 x 109/l platelet &lt; 100 x 109/l . Inadequate renal function define serum creatinine &gt; 1.25 x upper limit normal . Inadequate liver function define bilirubin &gt; upper limit normal AST/ALT &gt; 1.5 x upper limit normal ALP &gt; 3 x upper limit normal . Concurrent severe and/or uncontrolled comorbid medical condition ( i.e . uncontrolled infection , hypertension , ischaemic heart disease , myocardial infarction within previous 6 month , congestive heart failure ) Patients mixed mesodermal tumour . Patients borderline ovarian tumour tumour term 'possibly malignant ' . Adenocarcinoma unknown origin , histologically show mucinsecreting cancer think possible primary fallopian tube carcinoma . History previous malignancy within previous 5 year ( except curatively treat carcinoma situ uterine cervix , basal cell carcinoma skin ) , concurrent malignancy ( e.g . coexist endometrial cancer ) . History prior serious allergic reaction ( e.g . anaphylactic shock ) . History relative contraindication corticosteroid administration Pregnant lactate woman ( potentially fertile woman use adequate contraception ) . Symptomatic peripheral neuropathy &gt; NCICCTC grade II . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2007</verification_date>
</DOC>